You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEtoricoxib
Accession NumberDB01628  (DB07166)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionEtoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2). This reduces the generation of prostaglandins (PGs) from arachidonic acid.
Structure
Thumb
Synonyms
5-chloro-2-(6-Methylpyridin-3-yl)-3-(4-(methylsulfonyl)phenyl)pyridine
5-Chloro-3-(4-methanesulfonyl-phenyl)-6'-methyl-[2,3']bipyridinyl
5-chloro-6'-Methyl-3-(P-(methylsulfonyl)phenyl)-2,3'-bipyridine
ETORICOXIB
Etoricoxibum
L791456
External Identifiers
  • MK-663
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlgixNot Available
ArcoxiaNot Available
CoxyveenSolmarc Lifesciences
EtorixNot Available
NucoxiaNot Available
TauxibNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIWRX4NFY03R
CAS number202409-33-4
WeightAverage: 358.842
Monoisotopic: 358.054276131
Chemical FormulaC18H15ClN2O2S
InChI KeyInChIKey=MNJVRJDLRVPLFE-UHFFFAOYSA-N
InChI
InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3
IUPAC Name
5-chloro-3-(4-methanesulfonylphenyl)-2-(6-methylpyridin-3-yl)pyridine
SMILES
CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as bipyridines and oligopyridines. These are organic compounds containing two pyridine rings linked to each other.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassBipyridines and oligopyridines
Direct ParentBipyridines and oligopyridines
Alternative Parents
Substituents
  • 3-phenylpyridine
  • Bipyridine
  • Methylpyridine
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Sulfonyl
  • Sulfone
  • Azacycle
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.
PharmacodynamicsEtoricoxib is a COX-2 selective inhibitor (approximately 106 times more selective for COX-2 inhibition over COX-1). Currently it is approved in more than 60 countries worldwide but not in the US, where the Food and Drug Administration (FDA) require additional safety and efficacy data for etoricoxib before it will issue approval.
Mechanism of actionLike any other COX-2 selective inhibitor Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2). This reduces prostaglandins (PGs) generation from arachidonic acid.
Related Articles
AbsorptionBioavailability is 100% following oral administration.
Volume of distributionNot Available
Protein binding92%
Metabolism

Hepatic, primarily via CYP3A4.

SubstrateEnzymesProduct
Etoricoxib
Etoricoxib 1'-N'-oxideDetails
Etoricoxib
6-HydroxymethyletoricoxibDetails
6-Hydroxymethyletoricoxib
6-Hydroxymethyletoricoxib 1'-N'-oxideDetails
6-Hydroxymethyletoricoxib
6-Carboxy-etoricoxibDetails
6-Hydroxymethyletoricoxib
6-Hydroxymethyletoricoxib glucuronideDetails
Route of eliminationNot Available
Half life22 hours
ClearanceNot Available
ToxicityThis reduced activity is the cause of reduced gastrointestinal toxicity, as demonstrated in several large clinical trials performed with different COXIB (see below links on NEJM and The Lancet). Some clinical trials and meta-analysis showed that treatment with COXIB lead to increased incidence of cardiovascular adverse events compared to placebo
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Etoricoxib Action PathwayDrug actionSMP00695
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9776
Blood Brain Barrier+0.9399
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.845
P-glycoprotein inhibitor INon-inhibitor0.7624
P-glycoprotein inhibitor IINon-inhibitor0.9869
Renal organic cation transporterNon-inhibitor0.8267
CYP450 2C9 substrateNon-substrate0.6702
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.506
CYP450 1A2 substrateInhibitor0.6415
CYP450 2C9 inhibitorInhibitor0.8528
CYP450 2D6 inhibitorNon-inhibitor0.9268
CYP450 2C19 inhibitorInhibitor0.9087
CYP450 3A4 inhibitorInhibitor0.585
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8848
Ames testNon AMES toxic0.7952
CarcinogenicityNon-carcinogens0.6856
BiodegradationNot ready biodegradable0.9961
Rat acute toxicity2.4100 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9934
hERG inhibition (predictor II)Non-inhibitor0.8582
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00328 mg/mLALOGPS
logP3.7ALOGPS
logP2.79ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)19.69ChemAxon
pKa (Strongest Basic)4.96ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area59.92 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity95.04 m3·mol-1ChemAxon
Polarizability36.42 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Andrea Castellin, Paolo Stabile, Francesco Fontana, Ottorino De Lucchi, Andrea Caporale, Stefano Tartaggia, “PROCESS FOR PREPARING 1-(6-METHYLPYRIDIN-3-YL)-2-[4-(METHYLSULFONYL)PHENYL]ETHANONE, AN INTERMEDIATE OF ETORICOXIB.” U.S. Patent US20120232281, issued September 13, 2012.

US20120232281
General ReferencesNot Available
External Links
ATC CodesM01AH05
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabEtoricoxib may increase the anticoagulant activities of Abciximab.
AbirateroneThe serum concentration of Etoricoxib can be increased when it is combined with Abiraterone.
AcebutololEtoricoxib may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Aceclofenac.
AcenocoumarolEtoricoxib may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Etoricoxib.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Etoricoxib.
Alendronic acidThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Alendronic acid.
AliskirenEtoricoxib may decrease the antihypertensive activities of Aliskiren.
AlprenololEtoricoxib may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Etoricoxib.
AmikacinEtoricoxib may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideEtoricoxib may decrease the antihypertensive activities of Amiloride.
AmiodaroneThe metabolism of Etoricoxib can be decreased when combined with Amiodarone.
AncrodEtoricoxib may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Etoricoxib.
Antithrombin III humanEtoricoxib may increase the anticoagulant activities of Antithrombin III human.
ApixabanEtoricoxib may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Apremilast.
AprepitantThe serum concentration of Etoricoxib can be increased when it is combined with Aprepitant.
ArdeparinEtoricoxib may increase the anticoagulant activities of Ardeparin.
ArgatrobanEtoricoxib may increase the anticoagulant activities of Argatroban.
ArotinololEtoricoxib may decrease the antihypertensive activities of Arotinolol.
ArtemetherThe metabolism of Etoricoxib can be decreased when combined with Artemether.
AtazanavirThe metabolism of Etoricoxib can be decreased when combined with Atazanavir.
AtenololEtoricoxib may decrease the antihypertensive activities of Atenolol.
AtomoxetineThe metabolism of Etoricoxib can be decreased when combined with Atomoxetine.
AzapropazoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Etoricoxib.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Etoricoxib.
AzithromycinThe metabolism of Etoricoxib can be decreased when combined with Azithromycin.
BalsalazideEtoricoxib may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Etoricoxib.
BecaplerminEtoricoxib may increase the anticoagulant activities of Becaplermin.
BefunololEtoricoxib may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Etoricoxib.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Etoricoxib.
BenoxaprofenThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Benoxaprofen.
BetaxololEtoricoxib may decrease the antihypertensive activities of Betaxolol.
BetaxololThe metabolism of Etoricoxib can be decreased when combined with Betaxolol.
BevantololEtoricoxib may decrease the antihypertensive activities of Bevantolol.
BexaroteneThe serum concentration of Etoricoxib can be decreased when it is combined with Bexarotene.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Etoricoxib.
BisoprololEtoricoxib may decrease the antihypertensive activities of Bisoprolol.
BivalirudinEtoricoxib may increase the anticoagulant activities of Bivalirudin.
BoceprevirThe metabolism of Etoricoxib can be decreased when combined with Boceprevir.
BopindololEtoricoxib may decrease the antihypertensive activities of Bopindolol.
BortezomibThe metabolism of Etoricoxib can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Etoricoxib can be decreased when it is combined with Bosentan.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Etoricoxib.
BufuralolEtoricoxib may decrease the antihypertensive activities of Bufuralol.
BumetanideEtoricoxib may decrease the diuretic activities of Bumetanide.
BupranololEtoricoxib may decrease the antihypertensive activities of Bupranolol.
BupropionThe metabolism of Etoricoxib can be decreased when combined with Bupropion.
CaffeineThe metabolism of Etoricoxib can be decreased when combined with Caffeine.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Etoricoxib.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Etoricoxib.
CapecitabineThe metabolism of Etoricoxib can be decreased when combined with Capecitabine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Etoricoxib.
CarbamazepineThe metabolism of Etoricoxib can be increased when combined with Carbamazepine.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Etoricoxib.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Etoricoxib.
CarteololEtoricoxib may decrease the antihypertensive activities of Carteolol.
CarvedilolEtoricoxib may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Etoricoxib.
CeliprololEtoricoxib may decrease the antihypertensive activities of Celiprolol.
CeritinibThe serum concentration of Etoricoxib can be increased when it is combined with Ceritinib.
CertoparinEtoricoxib may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Etoricoxib.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etoricoxib.
ChlorpromazineThe metabolism of Etoricoxib can be decreased when combined with Chlorpromazine.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Etoricoxib.
CholecalciferolThe metabolism of Etoricoxib can be decreased when combined with Cholecalciferol.
CholestyramineCholestyramine can cause a decrease in the absorption of Etoricoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Etoricoxib.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Etoricoxib.
CimetidineThe metabolism of Etoricoxib can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Etoricoxib can be decreased when combined with Cinacalcet.
CitalopramThe metabolism of Etoricoxib can be decreased when combined with Citalopram.
Citric AcidEtoricoxib may increase the anticoagulant activities of Citric Acid.
ClarithromycinThe metabolism of Etoricoxib can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Etoricoxib can be decreased when combined with Clemastine.
ClobazamThe metabolism of Etoricoxib can be decreased when combined with Clobazam.
ClodronateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Clodronate.
ClomipramineThe metabolism of Etoricoxib can be decreased when combined with Clomipramine.
ClonixinThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Etoricoxib.
ClotrimazoleThe metabolism of Etoricoxib can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Etoricoxib can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Etoricoxib can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Etoricoxib can be decreased when combined with Cocaine.
ColesevelamColesevelam can cause a decrease in the absorption of Etoricoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Etoricoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.
ConivaptanThe serum concentration of Etoricoxib can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Etoricoxib can be decreased when combined with Crizotinib.
CyclosporineEtoricoxib may increase the nephrotoxic activities of Cyclosporine.
CyclosporineThe metabolism of Etoricoxib can be decreased when combined with Cyclosporine.
Cyproterone acetateThe serum concentration of Etoricoxib can be decreased when it is combined with Cyproterone acetate.
D-LimoneneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with D-Limonene.
Dabigatran etexilateEtoricoxib may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Etoricoxib can be decreased when it is combined with Dabrafenib.
DalteparinEtoricoxib may increase the anticoagulant activities of Dalteparin.
DanaparoidEtoricoxib may increase the anticoagulant activities of Danaparoid.
DarifenacinThe metabolism of Etoricoxib can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Etoricoxib can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Etoricoxib can be increased when it is combined with Dasatinib.
DaunorubicinEtoricoxib may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe serum concentration of Etoricoxib can be decreased when it is combined with Deferasirox.
DeferasiroxThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Deferasirox.
DelavirdineThe metabolism of Etoricoxib can be decreased when combined with Delavirdine.
DesipramineThe metabolism of Etoricoxib can be decreased when combined with Desipramine.
DesirudinEtoricoxib may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Desmopressin.
DexamethasoneThe serum concentration of Etoricoxib can be decreased when it is combined with Dexamethasone.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Etoricoxib.
DextranEtoricoxib may increase the anticoagulant activities of Dextran.
Dextran 40Etoricoxib may increase the anticoagulant activities of Dextran 40.
Dextran 70Etoricoxib may increase the anticoagulant activities of Dextran 70.
Dextran 75Etoricoxib may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Etoricoxib.
DicoumarolEtoricoxib may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Etoricoxib.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Etoricoxib.
DihydroergotamineThe metabolism of Etoricoxib can be decreased when combined with Dihydroergotamine.
DihydrostreptomycinEtoricoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DiltiazemThe metabolism of Etoricoxib can be decreased when combined with Diltiazem.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Etoricoxib.
DiphenhydramineThe metabolism of Etoricoxib can be decreased when combined with Diphenhydramine.
DoxorubicinEtoricoxib may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DoxycyclineThe metabolism of Etoricoxib can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Etoricoxib can be decreased when combined with Dronedarone.
DrospirenoneEtoricoxib may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Droxicam.
DuloxetineThe metabolism of Etoricoxib can be decreased when combined with Duloxetine.
Edetic AcidEtoricoxib may increase the anticoagulant activities of Edetic Acid.
EdoxabanEtoricoxib may increase the anticoagulant activities of Edoxaban.
EfavirenzThe serum concentration of Etoricoxib can be decreased when it is combined with Efavirenz.
EliglustatThe metabolism of Etoricoxib can be decreased when combined with Eliglustat.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Etoricoxib.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Etoricoxib.
EnoxaparinEtoricoxib may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe serum concentration of Etoricoxib can be decreased when it is combined with Enzalutamide.
EpirizoleThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Epirizole.
EpirubicinEtoricoxib may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneEtoricoxib may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etoricoxib.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etoricoxib.
ErythromycinThe metabolism of Etoricoxib can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Etoricoxib can be decreased when it is combined with Eslicarbazepine acetate.
EsmololEtoricoxib may decrease the antihypertensive activities of Esmolol.
Etacrynic acidEtoricoxib may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Etoricoxib.
Ethyl biscoumacetateEtoricoxib may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Etoricoxib.
EtofenamateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Etofenamate.
EtravirineThe serum concentration of Etoricoxib can be decreased when it is combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Etoricoxib is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Etoricoxib.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Etoricoxib.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Etoricoxib.
FloxuridineThe metabolism of Etoricoxib can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Etoricoxib can be decreased when combined with Fluconazole.
FlunixinThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Flunixin.
FluorouracilThe metabolism of Etoricoxib can be decreased when combined with Fluorouracil.
FluoxetineThe metabolism of Etoricoxib can be decreased when combined with Fluoxetine.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Etoricoxib.
FluvastatinThe metabolism of Etoricoxib can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Etoricoxib can be decreased when combined with Fluvoxamine.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Etoricoxib.
Fondaparinux sodiumEtoricoxib may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Etoricoxib.
FosamprenavirThe metabolism of Etoricoxib can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Etoricoxib can be increased when it is combined with Fosaprepitant.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Etoricoxib.
FosphenytoinThe metabolism of Etoricoxib can be increased when combined with Fosphenytoin.
FramycetinEtoricoxib may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideEtoricoxib may decrease the diuretic activities of Furosemide.
Fusidic AcidThe serum concentration of Etoricoxib can be increased when it is combined with Fusidic Acid.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Etoricoxib.
GemfibrozilThe metabolism of Etoricoxib can be decreased when combined with Gemfibrozil.
GentamicinEtoricoxib may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Haloperidol.
HaloperidolThe metabolism of Etoricoxib can be decreased when combined with Haloperidol.
HeparinEtoricoxib may increase the anticoagulant activities of Heparin.
HirulogEtoricoxib may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Etoricoxib is combined with HMPL-004.
HydralazineEtoricoxib may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Etoricoxib.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Etoricoxib.
Hygromycin BEtoricoxib may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Etoricoxib.
IbuproxamThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Icatibant.
IdarubicinEtoricoxib may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IdelalisibThe serum concentration of Etoricoxib can be increased when it is combined with Idelalisib.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Etoricoxib.
ImatinibThe metabolism of Etoricoxib can be decreased when combined with Imatinib.
ImipramineThe metabolism of Etoricoxib can be decreased when combined with Imipramine.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Etoricoxib.
IndenololEtoricoxib may decrease the antihypertensive activities of Indenolol.
IndinavirThe metabolism of Etoricoxib can be decreased when combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Etoricoxib.
IndoprofenThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Etoricoxib.
IsavuconazoniumThe metabolism of Etoricoxib can be decreased when combined with Isavuconazonium.
IsoniazidThe metabolism of Etoricoxib can be decreased when combined with Isoniazid.
IsoxicamThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Isoxicam.
IsradipineThe metabolism of Etoricoxib can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Etoricoxib can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Etoricoxib can be increased when it is combined with Ivacaftor.
KanamycinEtoricoxib may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Kebuzone.
KetoconazoleThe metabolism of Etoricoxib can be decreased when combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Etoricoxib.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Etoricoxib.
LabetalolEtoricoxib may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Etoricoxib.
LepirudinEtoricoxib may increase the anticoagulant activities of Lepirudin.
LevobunololEtoricoxib may decrease the antihypertensive activities of Levobunolol.
LidocaineThe metabolism of Etoricoxib can be decreased when combined with Lidocaine.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Etoricoxib.
LithiumThe serum concentration of Lithium can be increased when it is combined with Etoricoxib.
LopinavirThe metabolism of Etoricoxib can be decreased when combined with Lopinavir.
LorcaserinThe metabolism of Etoricoxib can be decreased when combined with Lorcaserin.
LornoxicamThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Etoricoxib.
LovastatinThe metabolism of Etoricoxib can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Etoricoxib.
LuliconazoleThe serum concentration of Etoricoxib can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Etoricoxib can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Etoricoxib can be decreased when combined with Lumefantrine.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Etoricoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Etoricoxib.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Etoricoxib.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etoricoxib.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Etoricoxib.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Etoricoxib.
MesalazineEtoricoxib may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Etoricoxib.
MetamizoleThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Metamizole.
MethadoneThe metabolism of Etoricoxib can be decreased when combined with Methadone.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Etoricoxib.
MethotrimeprazineThe metabolism of Etoricoxib can be decreased when combined with Methotrimeprazine.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etoricoxib.
MetipranololEtoricoxib may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Etoricoxib.
MetoprololEtoricoxib may decrease the antihypertensive activities of Metoprolol.
MetoprololThe metabolism of Etoricoxib can be decreased when combined with Metoprolol.
MetrizamideEtoricoxib may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MexiletineThe metabolism of Etoricoxib can be decreased when combined with Mexiletine.
MifepristoneThe metabolism of Etoricoxib can be decreased when combined with Mifepristone.
MirabegronThe metabolism of Etoricoxib can be decreased when combined with Mirabegron.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Etoricoxib.
MitotaneThe serum concentration of Etoricoxib can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Etoricoxib can be decreased when it is combined with Modafinil.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Etoricoxib.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Etoricoxib.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Etoricoxib.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etoricoxib.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Etoricoxib.
NadololEtoricoxib may decrease the antihypertensive activities of Nadolol.
NadroparinEtoricoxib may increase the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of Etoricoxib can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Etoricoxib.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Etoricoxib.
NCX 4016The risk or severity of adverse effects can be increased when Etoricoxib is combined with NCX 4016.
NefazodoneThe metabolism of Etoricoxib can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Etoricoxib can be decreased when combined with Nelfinavir.
NeomycinEtoricoxib may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Nepafenac.
NetilmicinEtoricoxib may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NetupitantThe serum concentration of Etoricoxib can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Etoricoxib can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Etoricoxib can be decreased when combined with Nicardipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Niflumic Acid.
NilotinibThe metabolism of Etoricoxib can be decreased when combined with Nilotinib.
NimesulideThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Nimesulide.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Etoricoxib.
OlaparibThe metabolism of Etoricoxib can be decreased when combined with Olaparib.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Etoricoxib.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etoricoxib.
OlsalazineEtoricoxib may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Etoricoxib.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Etoricoxib.
OmeprazoleThe metabolism of Etoricoxib can be decreased when combined with Omeprazole.
OrgoteinThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Orgotein.
OsimertinibThe serum concentration of Etoricoxib can be increased when it is combined with Osimertinib.
OtamixabanEtoricoxib may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Etoricoxib.
OxprenololEtoricoxib may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Oxyphenbutazone.
PalbociclibThe serum concentration of Etoricoxib can be increased when it is combined with Palbociclib.
PamidronateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Pamidronate.
PanobinostatThe metabolism of Etoricoxib can be decreased when combined with Panobinostat.
ParecoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Parecoxib.
ParomomycinEtoricoxib may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
ParoxetineThe metabolism of Etoricoxib can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Etoricoxib can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololEtoricoxib may decrease the antihypertensive activities of Penbutolol.
PentobarbitalThe metabolism of Etoricoxib can be increased when combined with Pentobarbital.
Pentosan PolysulfateEtoricoxib may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Etoricoxib.
PhenindioneEtoricoxib may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Etoricoxib can be increased when combined with Phenobarbital.
PhenprocoumonEtoricoxib may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Etoricoxib.
PhenytoinThe metabolism of Etoricoxib can be increased when combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etoricoxib.
PindololEtoricoxib may decrease the antihypertensive activities of Pindolol.
PiretanideEtoricoxib may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Etoricoxib.
PlicamycinEtoricoxib may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Etoricoxib.
PosaconazoleThe metabolism of Etoricoxib can be decreased when combined with Posaconazole.
PractololEtoricoxib may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Etoricoxib.
PrimidoneThe metabolism of Etoricoxib can be increased when combined with Primidone.
ProbenecidThe serum concentration of Etoricoxib can be increased when it is combined with Probenecid.
PromazineThe metabolism of Etoricoxib can be decreased when combined with Promazine.
PropacetamolThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Propacetamol.
PropranololEtoricoxib may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Etoricoxib.
Protein CEtoricoxib may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeEtoricoxib may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Etoricoxib is combined with PTC299.
PuromycinEtoricoxib may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PyrimethamineThe metabolism of Etoricoxib can be decreased when combined with Pyrimethamine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Etoricoxib.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Etoricoxib.
QuinidineThe metabolism of Etoricoxib can be decreased when combined with Quinidine.
QuinineThe metabolism of Etoricoxib can be decreased when combined with Quinine.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Etoricoxib.
RanolazineThe metabolism of Etoricoxib can be decreased when combined with Ranolazine.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Etoricoxib.
ResveratrolThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Resveratrol.
ReviparinEtoricoxib may increase the anticoagulant activities of Reviparin.
RibostamycinEtoricoxib may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RifabutinThe metabolism of Etoricoxib can be increased when combined with Rifabutin.
RifampicinThe metabolism of Etoricoxib can be increased when combined with Rifampicin.
RifapentineThe metabolism of Etoricoxib can be increased when combined with Rifapentine.
RisedronateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Risedronate.
RitonavirThe metabolism of Etoricoxib can be decreased when combined with Ritonavir.
RivaroxabanEtoricoxib may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Etoricoxib.
RolapitantThe metabolism of Etoricoxib can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Etoricoxib can be decreased when combined with Ropinirole.
SalicylamideThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Etoricoxib.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Etoricoxib.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Etoricoxib.
SaquinavirThe metabolism of Etoricoxib can be decreased when combined with Saquinavir.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Etoricoxib.
SecobarbitalThe metabolism of Etoricoxib can be increased when combined with Secobarbital.
SeratrodastThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Seratrodast.
SertralineThe metabolism of Etoricoxib can be decreased when combined with Sertraline.
SildenafilThe metabolism of Etoricoxib can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Etoricoxib can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Etoricoxib can be increased when it is combined with Simeprevir.
SorafenibThe metabolism of Etoricoxib can be decreased when combined with Sorafenib.
SotalolEtoricoxib may decrease the antihypertensive activities of Sotalol.
SpectinomycinEtoricoxib may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Etoricoxib.
SpironolactoneEtoricoxib may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Etoricoxib is combined with SRT501.
St. John's WortThe serum concentration of Etoricoxib can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Etoricoxib can be increased when it is combined with Stiripentol.
StreptomycinEtoricoxib may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinEtoricoxib may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfadiazineThe metabolism of Etoricoxib can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Etoricoxib can be decreased when combined with Sulfamethoxazole.
SulfasalazineEtoricoxib may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Etoricoxib.
SulfisoxazoleThe metabolism of Etoricoxib can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Etoricoxib.
SulodexideEtoricoxib may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Etoricoxib.
TacrolimusEtoricoxib may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Etoricoxib.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Etoricoxib.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Technetium Tc-99m Medronate.
TelaprevirThe metabolism of Etoricoxib can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Etoricoxib can be decreased when combined with Telithromycin.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Etoricoxib.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Etoricoxib.
TenofovirThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Tenofovir.
TenofovirThe metabolism of Etoricoxib can be decreased when combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Etoricoxib.
TepoxalinThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Tepoxalin.
TerbinafineThe metabolism of Etoricoxib can be decreased when combined with Terbinafine.
TeriflunomideThe serum concentration of Etoricoxib can be decreased when it is combined with Teriflunomide.
TeriflunomideThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Teriflunomide.
TheophyllineThe metabolism of Etoricoxib can be decreased when combined with Theophylline.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Etoricoxib.
ThioridazineThe metabolism of Etoricoxib can be decreased when combined with Thioridazine.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Etoricoxib.
TicagrelorThe metabolism of Etoricoxib can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Etoricoxib can be decreased when combined with Ticlopidine.
TiludronateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Tiludronate.
TimololEtoricoxib may decrease the antihypertensive activities of Timolol.
TipranavirThe metabolism of Etoricoxib can be decreased when combined with Tipranavir.
TobramycinEtoricoxib may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TocilizumabThe serum concentration of Etoricoxib can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Etoricoxib can be decreased when combined with Tolbutamide.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Etoricoxib.
TorasemideEtoricoxib may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Etoricoxib.
TranilastThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Tranilast.
TranylcypromineThe metabolism of Etoricoxib can be decreased when combined with Tranylcypromine.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Etoricoxib.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Etoricoxib.
TriamtereneEtoricoxib may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Etoricoxib.
TrimethoprimThe metabolism of Etoricoxib can be decreased when combined with Trimethoprim.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Etoricoxib.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Etoricoxib.
Valproic AcidThe metabolism of Etoricoxib can be decreased when combined with Valproic Acid.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Etoricoxib.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Etoricoxib.
VemurafenibThe serum concentration of Etoricoxib can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Etoricoxib can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Etoricoxib can be decreased when combined with Verapamil.
VoriconazoleThe metabolism of Etoricoxib can be decreased when combined with Voriconazole.
WarfarinEtoricoxib may increase the anticoagulant activities of Warfarin.
XimelagatranEtoricoxib may increase the anticoagulant activities of Ximelagatran.
ZafirlukastThe metabolism of Etoricoxib can be decreased when combined with Zafirlukast.
ZaltoprofenThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Etoricoxib.
ZiprasidoneThe metabolism of Etoricoxib can be decreased when combined with Ziprasidone.
Zoledronic acidThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Zomepirac.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P: Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):85-94. Epub 2006 Jul 3. [PubMed:17164136 ]
  4. FitzGerald GA: COX-2 in play at the AHA and the FDA. Trends Pharmacol Sci. 2007 Jul;28(7):303-7. Epub 2007 Jun 18. [PubMed:17573128 ]
  5. Yuan Y, Hunt RH: Global gastrointestinal safety profile of etoricoxib and lumiracoxib. Curr Pharm Des. 2007;13(22):2237-47. [PubMed:17691997 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Takemoto JK, Reynolds JK, Remsberg CM, Vega-Villa KR, Davies NM: Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin Pharmacokinet. 2008;47(11):703-20. [PubMed:18840026 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on August 30, 2007 09:49 / Updated on August 17, 2016 12:23